HOTH - Hoth Therapeutics partners with Camargo Pharma for HT-001 IND

Hoth Therapeutics ([[HOTH]] +9.6%) has signed an agreement with Camargo Pharmaceutical Services to facilitate the writing and submission of the Investigational New Drug application for its HT-001 topical product to the U.S. FDA for initiating the first clinical trial.The company will write, prepare, and submit an IND in the electronic Common Technical Document ((eCTD)) format to the US FDA.HT-001 is a topical product being developed for the treatment of rash and skin disorders associated with initial and repeat courses of epidermal growth factor receptor ((EGFR)) inhibitor therapy.Hoth had inked a deal with Charles River Laboratories ([[CRL]] +0.0%) to initiate preclinical studies of HT-001, last month.

For further details see:

Hoth Therapeutics partners with Camargo Pharma for HT-001 IND